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ABSTRACT
Background: Clinically relevant drug–drug interac-
tions (DDIs) must be recognized in a timely manner 
and managed appropriately to prevent adverse drug 
reactions or therapeutic failure. Because the evidence 
for most DDIs is based on case reports or poorly docu- 
mented clinical information, there is a need for better 
assessment of their clinical relevance. 
Objective: This study evaluates the interdisciplin-
ary agreement between rheumatologists and clinical 
(hospital) pharmacists in assessing the clinical relevance 
of DDIs with disease-modifying antirheumatic drugs 
(DMARDs) and non-DMARD medications. 
Methods: Potential DDIs were identified from the 
medical literature using MEDLINE and EMBASE for 
the years 1968–2009. The following search terms 
were used for the key word, title, and abstract sections 
of the publications: interaction(s), DMARD, disease-
modifying antirheumatic drug(s), antirheumatic, rheu-
matology, rheumatoid arthritis, and the names of 
the individual DMARDs of interest (abatacept, 
adalimumab, anakinra, auranofin, aurothioglucose, 
aurothiomalate, D-penicillamine, etanercept, gold, 
[hydroxy]-chloroquine, interleukin-1 receptor antago-
nist, IL1-RA, infliximab, leflunomide, methotrexate, 
rituximab, and sulfasalazine/sulphasalazine). Reference 
lists of the retrieved publications were searched for fur-
ther information on potential DDIs. All pharmacody-
namic or pharmacokinetic DDIs between a DMARD 
and a non-DMARD identified were included in the 
study, with the exception of evidence regarding 
DMARD doses higher than used in the treatment of 
rheumatoid arthritis and interactions with phytothera- 
peutic or homeopathic preparations. Using a standard 
information set for each DDI (eg, from product label-
ing, textbooks, and the medical literature), a group of 
rheumatologists and a group of clinical pharmacists 
independently assessed whether the individual drug–
DMARD combinations interacted and whether they 
required immediate intervention. Both groups con-
sisted of 3 members (2 men and 1 woman), aged 40 to 
60 years, who had >5 years of clinical experience and 
were currently involved in clinical practice in large, 
nonacademic teaching hospitals in the Netherlands.
Results: Forty potential DDIs with DMARDs were 
retrieved and assessed by the 2 groups. For 30 (75%) 
of these, rheumatologists and clinical pharmacists 
agreed about the requirement for immediate interven-
tion. Specifically, 17 drug combinations (43%) were 
judged to interact and to require immediate interven-
tion, and 13 combinations (33%) were judged either 
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doctors believe that these systems yield a large num-
ber of DDIs with questionable or unclear clinical rele- 
vance while failing to detect all relevant DDIs.11 
Furthermore, these systems fail to provide identifiable 
patient- and medication-related risk factors. These 
shortcomings allow users to doubt the quality of the 
system and to ignore DDI alerts.13,15 For these rea-
sons, a transparent and reproducible assessment of 
potential DDIs is essential before drug combinations 
are entered into a CIS.
The Working Group on Pharmacotherapy and 
Drug Information, responsible for the maintenance of 
the CIS of the Royal Dutch Association for the Ad-
vancement of Pharmacy, developed a structured assess-
ment for potential DDIs in an effort to reach a trans-
parent and reproducible assessment procedure. The 
assessment is based on the evaluation of 4 core pa-
rameters of DDIs: the quality of the evidence on the 
specific DDI; the severity of the adverse reaction to 
the DDI; patient, medication, or disease characteris-
tics that increase the risk of adverse reactions to the 
drug combination; and the incidence of adverse reac-
tions when the combination is given.16 These 4 core 
parameters are equally weighted in a multidisciplinary 
assessment.16 On the basis of this assessment, drug com-
binations are selected for incorporation into the CIS. 
Although the perception of sensitivity and speci- 
ficity of the alerts generated by the CIS may improve 
with the use of a structured assessment procedure, dif-
ferences may exist in the assessment of clinical rele-
vance between medical and pharmacologic specialties. 
When these differences are not considered, the sensi-
tivity and specificity of the CIS alerts may be perceived 
as suboptimal. A search of the literature did not iden-
tify any studies on the difference between medical 
specialty groups in the assessment of the clinical rele-
vance of DDIs in rheumatology. We therefore per-
formed a study to compare and contrast the as- 
sessments of rheumatologists and clinical (hospital) 
pharmacists regarding the clinical relevance of DDIs 
with various disease-modifying antirheumatic drugs 
(DMARDs) and other medications.
METHODS
Selection of Potential Drug–Drug Interactions
Using product leaflets and textbooks,7,8 we identi-
fied potential DDIs with drugs used as DMARDs. We 
also searched the medical literature using MEDLINE17 
and EMBASE18 for the years 1968–2009, with the 
not to interact or to interact but not to require imme-
diate intervention. For 10 combinations (25%), rheu-
matologists and clinical pharmacists were not in 
agreement. Overall, agreement between the groups 
was good (κ = 0.80) for judging whether the drug 
combinations were interactions, and agreement was 
fair (κ = 0.39) for judging whether immediate inter-
vention was required. Prospective analysis of the data 
showed that rheumatologists tended to recommend 
immediate intervention more often when the adverse 
reaction to the DDI involved an increased risk of tox-
icity of the DMARD. In contrast, clinical pharmacists 
more often advocated immediate intervention when 
the adverse reaction involved decreased effectiveness 
of the DMARD. 
Conclusion: For a subset of DMARD–drug combi-
nations, rheumatologists and clinical pharmacists dif-
fered in their assessments of clinical relevance. (Clin 
Ther. 2009;31:1737–1746) © 2009 Excerpta Medica 
Inc.
Key words: drug–drug interaction, disease-modifying 
antirheumatic drug, rheumatoid arthritis, assessment. 
INTRODUCTION
Pharmacotherapy is the mainstay of treatment for 
rheumatoid arthritis. Because of advanced age and the 
presence of comorbid conditions in this population, 
patients may receive multiple medications and hence 
are at risk for drug–drug interactions (DDIs).1,2 To 
prevent potential adverse drug reactions or therapeu-
tic failure, clinically relevant DDIs must be recognized 
in a timely manner and managed appropriately.
Although information on potential DDIs is avail-
able from reviews,3–6 product leaflets, textbooks,7,8 
and the medical literature, several barriers impede rec- 
ognition of the clinical importance of a DDI. The evi-
dence for most DDIs is based on case reports or poorly 
documented clinical information. Drug-interaction 
compendia are inconsistent in their grading of the 
relevance of DDIs.9 Manual recognition of potentially 
relevant DDIs, in contrast to computer-generated 
alerts, has been reported to miss many DDIs that are 
potentially clinically relevant and to result in a large 
variety of detected DDIs among individual observ-
ers.10 Although computerized drug-interaction alert 
systems (CISs) may improve sensitivity for the recog-
nition of potentially relevant DDIs, they have a num-
ber of important drawbacks.11–15 Pharmacists and 
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(4) the incidence of the adverse reaction when the com-
bination is administered, according to the literature. 
The quality level of evidence for DDIs was defined 
as follows16: category 0 indicated pharmacodynamic 
animal studies, in vitro studies with limited predictive 
value for the human in vivo situation, or “data on 
file”; category 1 indicated incomplete case reports (no 
rechallenge or dechallenge; presence of factors other 
than a DDI that explain the adverse reaction); catego-
ry 2 indicated well-documented case reports or retro-
spective analyses of case series; category 3 indicated 
controlled interaction studies with surrogate end 
points; and category 4 indicated controlled interaction 
studies with clinically relevant end points. The stan-
dard data set also contained the main publications on 
the DDI. These publications could either support or 
deny the existence of the DDI. All of the information 
in the standard data set was provided electronically as 
well as on paper. 
Expert Assessment
On the basis of the standard data set for each po-
tential DDI, 3 rheumatologists and 3 clinical pharma-
cists were asked to assess the DDI individually. The 
rheumatologists and clinical pharmacists were select-
ed on the basis of >5 years of clinical experience and 
current involvement in clinical practice. The rheuma-
tologists and clinical pharmacists (2 men and 1 wom- 
an in both groups; aged 40–60 years) all worked 
in large, nonacademic teaching hospitals in the 
Netherlands.
The following 2 questions, which required a “yes” or 
“no” response, were used to assess the potential DDIs: 
(1) “On the basis of the information provided about the 
DDI, would you conclude that this combination of 
drugs will interact?” and (2) “When you judge this com-
bination to interact, is any immediate intervention re-
quired?” Immediate intervention was defined as any 
action required at the moment the combination is rec-
ognized to prevent medication-related problems such as 
adverse drug reactions or suboptimal efficacy, as judged 
by the individual rheumatologist or clinical pharmacist 
on the basis of the evidence presented. Potential imme-
diate interventions included the following: adjusted 
monitoring of therapy effectiveness or tolerability in the 
near future, adjusted provision of patient education 
about potential symptoms indicating adverse effects, 
appointments for therapeutic drug monitoring, dose 
adjustments, or prescription of an alternative drug.
following search terms for the key word, title, and 
abstract sections of the publications: interaction(s), 
DMARD, disease-modifying antirheumatic drug(s), 
antirheumatic, rheumatology, rheumatoid arthritis, and 
the names of the individual DMARDs of interest (abata- 
cept, adalimumab, anakinra, auranofin, aurothioglu-
cose, aurothiomalate, D-penicillamine, etanercept, gold, 
[hydroxy]chloroquine, interleukin-1 receptor antago-
nist, IL1-RA, infliximab, leflunomide, methotrexate, 
rituximab, and sulfasalazine/sulphasalazine). Refer-
ence lists of the retrieved publications were searched 
for further information on potential DDIs.
All potential DDIs with DMARDs were included 
except for the following. First, we excluded combina-
tions of 2 DMARDs, DMARDs with systemic corti-
costeroids, and DMARDs with NSAIDs because, in 
most cases, these medications are combined by rheu-
matologists intentionally to improve clinical response. 
Although we are well aware of the (relative) contrain-
dications for the combination of NSAIDs with metho-
trexate, anti–tumor necrosis factor-α antagonists with 
rituximab, or drugs with overlapping toxicity profiles 
(eg, hepatotoxicity), these combinations were not as-
sessed in this study. Second, we excluded combina-
tions when the evidence for potential DDIs was based 
on dose levels far higher than those used in the treat-
ment of rheumatoid arthritis (eg, methotrexate or 
azathioprine at doses used in oncology, or chloroquine 
as an antimalarial agent). Third, we excluded combi-
nations of DMARDs with food supplements or phyto-
therapeutic or homeopathic preparations. Finally, we 
excluded pharmaceutical DDIs (eg, incompatibilities 
in pharmaceutical containers with solutions for paren-
teral administration).
Assessment of Potential Drug–Drug Interactions
Standard Information Package for Each Interaction
For every potential DDI, a standard data set was 
prepared containing comprehensive information on 
the 4 core parameters of the DDI, as described earli-
er.16 These included the following: (1) the quality level 
of the evidence on the drug combination, categorized 
from 0 to 416; (2) a description of the adverse reaction 
from the combination, including the severity and the 
mechanism of the DDI; (3) characteristics of the pa-
tient (eg, age, sex), disease (eg, renal and hepatic func-
tion), or medication (eg, dose, route of administration) 
when the risk of an adverse reaction from the poten-
tial DDI is dependent on these characteristics; and 
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Assessment of Potential Drug–Drug Interactions
Table I shows the assessment by the 2 specialty 
groups as to whether the drug combinations were 
interactions (ie, DDIs). The results represent good agree-
ment between the groups (mean [SD] κ = 0.80 [0.11]). 
Within the groups, the 40 combinations were judged 
unanimously in 29 (73%) and 26 (65%) of the 
cases by clinical pharmacists and rheumatologists, re-
spectively (data not shown).
Table I also shows the assessment by the 2 specialty 
groups as to whether the drug combinations required 
immediate intervention. The results represent fair agree-
ment between the groups (mean [SD] κ = 0.39 [0.15]). 
Within the groups, the 40 combinations were judged 
unanimously in 27 (68%) and 17 (43%) of the 
cases by clinical pharmacists and rheumatologists, re-
spectively (data not shown).
Tables II through IV display specific information 
on the drug combinations. For 30 (75%) of the drug 
combinations, rheumatologists and clinical pharma-
cists agreed about the requirement for immediate in-
tervention. Table II details the 17 drug combinations 
(43%) judged by both groups to be DDIs and to re-
quire immediate intervention.20–45 Table III details the 
13 drug combinations (33%) that were judged by 
Data Analysis
For both specialty groups (rheumatologists and 
clinical pharmacists), the data from the individual as-
sessments were pooled separately. Outcomes per 
group were based on the opinion of the majority. On 
the basis of these assessments, the potential DDIs were 
divided into 3 groups: (1) drug combinations judged 
by both specialty groups as DDIs that require immedi-
ate intervention; (2) combinations judged by both 
specialty groups as either not interacting and there-
fore not requiring immediate intervention, or interact-
ing but not requiring immediate intervention; and 
(3) combinations for which the rheumatologists and 
clinical pharmacists disagreed whether the combina-
tion interacted or whether immediate intervention 
was required.
The adverse reaction of each individual drug com-
bination was prospectively grouped into 1 of 5 cate-
gories: (1) increased toxicity of the DMARD or (2) the 
non-DMARD, (3) decreased effectiveness of the 
DMARD or (4) the non-DMARD, or (5) other. When 
the adverse reaction of the DDI involved increased 
toxicity associated with both the DMARD and the 
non-DMARD individually, this toxicity was catego-
rized as “increased toxicity of the DMARD.”
Statistical Analysis
Assessments of the DDIs per specialty group were 
presented using 2 × 2 tables. To assess the interob-
server variability, Cohen’s κ was calculated. The 
L values of <0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61 to 
0.80, and 0.81 to 1.00 were classified as poor, fair, 
moderate, good, or very good agreement, respectively, 
between the specialty groups.19 Differences in assess-
ments of clinical relevance between the specialty 
groups per adverse-reaction category were analyzed 
using the nonparametric McNemar test in SPSS 13.0 
(SPSS Inc., Chicago, Illinois). P < 0.05 was considered 
significant.
RESULTS
Selection of Potential Drug–Drug Interactions
Forty potentially interacting drug combinations 
with DMARDs were identified within the selection 
criteria. The highest level of evidence found for the 
potential DDIs was level 3 in 57%, level 2 in 5%, level 
1 in 18%, and level 0 in 20%. Level-4 evidence was 
not found for any of the drug combinations. No evi-
dence for DDIs with biologic agents was found.
Table I.  Assessments of the drug combinations 
with disease-modifying antirheumatic 
drugs by the 2 specialty groups.
  
 No Yes Total
Assessment as a  
drug–drug interaction*
  Clinical pharmacists
    No 8 3 11
    Yes 0 29 29
Total 8 32 40
Assessment of need for  
immediate intervention†
  Clinical pharmacists
    No 13 5 18
    Yes 5 17 22
Total 18 22 40 
 * Mean (SD) κ = 0.80 (0.11) between the specialty groups. 
 †  Mean (SD) κ = 0.39 (0.15) between the specialty groups.
Rheumatologists
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their assessments of individual drug combinations 
when the adverse reaction involved decreased effec-
tiveness of the DMARD; specifically, clinical pharma-
cists were more likely to judge the combination as 
requiring immediate intervention.
After excluding the drug combinations that did not 
interact and did not require immediate intervention ac-
cording to both specialty groups, 27 of the 40 combina-
tions remained. Both groups achieved a sensitivity of 
81% for these combinations (ie, both groups identified 
22 of 27 combinations as requiring immediate interven-
tion). Specificity for both groups was 19% (ie, for 5 of 
both groups either not to interact or to interact 
but not to require immediate intervention.46–58 
Table IV outlines the 10 drug combinations (25%) for 
which the rheumatologists and clinical pharmacists 
disagreed.59–70
Table V shows the expert opinions about the need 
for immediate intervention according to the adverse-
reaction category. Rheumatologists, compared with 
clinical pharmacists, tended to recommend immediate 
intervention more often for drug combinations with 
an increased risk of toxicity of the DMARD. Rheuma-
tologists and clinical pharmacists tended to differ in 
Table II.  Drug combinations with disease-modifying antirheumatic drugs (DMARDs) assessed by both 
specialty groups as drug–drug interactions requiring immediate intervention.
  Level of 
DMARD Combining Agent Evidence* Adverse Reaction Ref
Azathioprine Allopurinol 3 ↑ Azathioprine toxicity 20, 21
 Doxorubicin 3 ↑ Hepatotoxicity 22
 Warfarin 2 ↓ Anticoagulant activity 23, 24
Chloroquine Praziquantel 3 ↓ AUC praziquantel by 65% 25
 Drugs that increase the  0 ↑ Cardiac arrhythmia  – 
   QT interval
D-penicillamine Digoxin 3 ↓ AUC digoxin by 40%–64% 26
 Iron salts 3 ↓ AUC D-penicillamine by  27 
     35%–60%
Hydroxychloroquine Cardiac glycosides 2 ↑ Cmax digoxin by 4-fold 28, 29
Leflunomide Activated charcoal/resins 3 ↓ Plasma t1/2 of  30 
     A77 1726 by 10-fold
 Warfarin 1 ↑ Anticoagulant activity 31, 32
Methotrexate Acitretin/retinoids 3 ↑ Hepatotoxicity due to  33–35 
   ↑ AUC MTX
 Cotrimoxazole/trimethoprim 3 ↑ Bone marrow depression 36–39
 Isoniazid 3 ↑ Hepatotoxicity 40, 41
 Probenecid 3 ↑ C24h MTX by 3- to 4-fold 42, 43
Sulfasalazine Digoxin 3 ↓ AUC digoxin by 50% 44
 Isoniazid 3 ↑ Hepatotoxicity 40
 Talinolol 3 ↓ AUC talinolol by 90% 45 
Ref = references; ↑ = increase or increased risk; ↓ = decrease or decreased risk; A77 1726 = active metabolite of lefluno-
mide; MTX = methotrexate.
* Category 0 = pharmacodynamic animal studies, in vitro studies with limited predictive value for the human in vivo situ-
ation, or “data on f ile”; category 1 = incomplete case reports (no rechallenge or dechallenge; presence of factors other 
than a drug–drug interaction that explain the adverse reaction); category 2 = well-documented case reports or retrospec-
tive analyses of case series; category 3 = controlled interaction studies with surrogate end points; category 4 = controlled 
interaction studies with clinically relevant end points.
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nations had information on the existence of a po- 
tential DDI.71 When translating these results to the 
population with rheumatoid arthritis, one may also 
expect underreporting of potentially clinically relevant 
DDIs with DMARDs. Guidelines for research on po-
tential DDIs for newly registered drugs72 may expand 
our knowledge of potential DDIs. However, drugs 
that have been marketed for several years may lack 
this information. This is reflected by the relative- 
ly high proportion (43%) of combinations in our 
study with evidence quality categorized as grade 0 to 
2 and the lack of grade-4 evidence for any of the 
combinations. 
In our study, immediate intervention was broadly 
defined as any action taken to prevent medication- 
related problems (eg, adverse drug reactions or subop-
timal efficacy) or to avoid the interaction. Differences 
in judgment between the specialty groups may be due 
to differing perceptions about the degree to which the 
DDI can be controlled (eg, the likelihood of prevent-
ing the adverse reaction). For example, when the drug 
27 combinations, the group would generate an alert 
or take immediate action, whereas the other group 
would not require any immediate intervention).
DISCUSSION
For 30 of 40 (75%) potentially interacting drug com-
binations involving DMARDs, rheumatologists and 
clinical pharmacists agreed about the requirement for 
immediate intervention or no intervention at all. Over- 
all, rheumatologists were more likely to judge a poten-
tial DDI as requiring immediate intervention when the 
drug combination increased the risk of DMARD tox-
icity, whereas clinical pharmacists were more likely to 
judge a potential DDI as requiring immediate inter-
vention when the drug combination resulted in a de-
crease in effectiveness of the applied DMARD.
Our literature search identified only 40 potential 
DDIs among all possible drug combinations with 
DMARDs. A German study in a general population 
participating in a health-screening program found 
that only 7.5% of the total prescribed drug combi- 
Table III.  Drug combinations with disease-modifying antirheumatic drugs (DMARDs) assessed by both spe-
cialty groups as not requiring immediate intervention.*
  Level of 
DMARD Combining Agent Evidence† Adverse Reaction Ref
Aurothiomalate ACE inhibitors 1 Nitritoid reactions 46, 47
Azathioprine Lamivudine 1 ↑ Pancreatitis 48
 Mycophenolate mofetil 0 ↑ Hematologic toxicity 49
 ACE inhibitors 3 ↑ Neutropenia and ↑ anemia 50, 51
Chloroquine Codeine None ↓ Analgesic effectiveness of codeine 49
 Metronidazole 1 Acute dystonia 52
 Neuromuscular  0 ↑ Neuromuscular blockade 53 
 blocking agents
 Mefloquine 0 ↑ QT-interval prolongation, ↑ convulsions,  
   ↑ mefloquine plasma concentrations 54
D-penicillamine Clozapine 0 ↑ Agranulocytosis 55
 Oral contraceptives 1 ↑ Macromastia 56
 Tricyclic antidepressants 0 ↑ Myasthenia gravis 57
Gold salts Chelating agents  0 Changes in gold distribution and elimination 49
Methotrexate Theophylline 3 ↓ Theophylline clearance 58 
Ref = references; ACE = angiotensin-converting enzyme; ↑ = increase or increased risk; ↓ = decrease or decreased risk.
 * The drug combinations were judged either not to interact or to interact but not to require immediate intervention.
 † For explanation of categories, see Table II.
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Table IV.  Drug combinations with disease-modifying antirheumatic drugs (DMARDs) for which rheumatolo-
gists and clinical pharmacists disagreed about whether the combination interacted or whether im-
mediate intervention was required.
 Immediate Intervention? 
 Combining Level of   Clinical 
DMARD Agent Evidence* Adverse Reaction Rheumatologists Pharmacists Ref
Azathioprine Cotrimoxazole 3 ↑ Neutropenia/  No Yes 59 
    thrombocytopenia
Chloroquine Cimetidine 3 ↓ Elimination of  Yes No 60 
    chloroquine
 Magnesium       
  trisilicate/kaolin 3 ↓ AUC chloroquine No Yes 61
D-penicillamine Antacids 3 ↓ AUC D-penicillamine  No Yes 62 
    by 30%–40%
 L-dopa 1 ↑ AUC L-dopa by 50% Yes No 63
Leflunomide Itraconazole 1 ↑ Hepatotoxicity Yes No 64
 Rifampicin 3 ↑ Cmax A77 1726 by 40% Yes No 65
Methotrexate Penicillins 3 ↑ MTX toxicity Yes No 66, 67
Sulfasalazine Ampicillin/ 3 ↓ AUC sulfapyridine No Yes 68, 69 
  rifampicin   by 60%–65%
 Iron salts 3 ↓ C5h sulfasalazine No Yes 70 
Ref = references; ↑ = increase or increased risk; ↓ = decrease or decreased risk; A77 1726 = active metabolite of lefluno-
mide; MTX = methotrexate.
 * For explanation of categories, see Table II.
Table V.  Assessments of the need for immediate intervention according to adverse-reaction category for drug 
combinations with disease-modifying antirheumatic drugs (DMARDs) by the 2 specialty groups.
 No. of   
 Combinations  Clinical 
Adverse-Reaction Category in Category Rheumatologists Pharmacists P*
Increased toxicity of DMARD 19 14 9 0.13
Decreased effectiveness of DMARD 7 2 6 0.13
Increased toxicity of non-DMARD 4 2 1 1.00
Decreased effectiveness of non-DMARD 6 5 5 1.00
Other 4 1 1 1.00 
* Differences in assessments between the specialty groups per adverse-reaction category were analyzed using the nonpara-
metric McNemar test.
Requiring Immediate Intervention
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combination shows an interaction based on decreased 
absorption from the gastrointestinal tract due to 
complexation (eg, chloroquine/magnesium trisilicate, 
d-penicillamine/antacids, d-penicillamine/iron salts, 
d-penicillamine/digoxin, or sulfasalazine/iron salts), the 
DDI can be controlled by adjusting the dosing times 
of the medications. Clinical pharmacists judged that 
all of these DDIs would have required immediate in-
tervention, whereas rheumatologists considered im-
mediate intervention to be required for only 2 of these 
interactions. These results highlight the differences in 
points of view between the specialty groups and the 
need for a multidisciplinary approach when assessing 
the relevance of a drug combination.
Our study has some limitations that should be ad-
dressed. First, the differences in results between the 
specialty groups may be specific to the field of rheu-
matology or the particular setting (ie, hospital). To our 
knowledge, no studies on this subject have been pub-
lished in other fields of medicine that have evaluated 
DDIs. Second, no effort was made to reach consensus 
between the groups, so the results presented indicate 
the maximum contrast between the groups. Third, the 
rheumatologists and clinical pharmacists were not 
blinded to the objective of the study, and this may 
have been a source of bias. Despite these limitations, 
our study provides valuable information about differ-
ences in the assessment of the clinical relevance of 
DDIs between 2 specialties involved in the care of 
patients with rheumatoid arthritis.
CONCLUSIONS
Rheumatologists and clinical pharmacists differed in 
their assessments of clinical relevance for 10 out of 
40 DMARD–drug combinations. To prevent drug- 
related problems, it may be necessary to eradicate dis-
cordant interdisciplinary attitudes and institute multi-
disciplinary judgment of the relevance of DDIs. 
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